ENTRY       D10582            Mixture   Drug
NAME        Dasabuvir, ombitasvir, paritaprevir and ritonavir;
            Viekira pak (TN)
COMPONENT   (Dasabuvir sodium hydrate [DR:D10581] | Dasabuvir [DR:D10553]), (Ombitasvir hydrate [DR:D10598] | Ombitasvir [DR:D10576]), (Paritaprevir hydrate [DR:D10597] | Paritaprevir [DR:D10580]), Ritonavir [DR:D00427]
CLASS       Antiviral
             DG03198  Anti-HCV agent
            Metabolizing enzyme substrate
             DG02918  CYP2C8 substrate
             DG01633  CYP3A/CYP3A4 substrate
            Metabolizing enzyme inhibitor
             DG02852  CYP3A/CYP3A4 inhibitor
              DG01522  CYP3A4 inhibitor
             DG02887  UGT1A1 inhibitor
            Transporter substrate
             DG01665  ABCB1 substrate
             DG01913  ABCG2 substrate
             DG02856  SLCO1B1 substrate
             DG02932  SLCO1B3 substrate
            Transporter inhibitor
             DG02862  ABCG2 inhibitor
             DG02865  SLCO1B1 inhibitor
             DG02907  SLCO1B3 inhibitor
REMARK      ATC code: J05AP52
EFFICACY    Antiviral
  DISEASE   Chronic hepatitis C virus infection [DS:H00413]
COMMENT     Dasabuvir is an inhibitor of UGT1A1 and P-glycoprotein (P-gp). It is metabolized by CYP2C8 and it is a substrate for P-glycoprotein (P-gp).
            Ombitasvir is an inhibitor of UGT1A1, and it is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP).
            Paritaprevir is an inhibitor of UGT1A1, and it is an inhibitor of the following transporters: OATP1B1 and OATP1B3. It is metabolized by CYP3A4 and it is a substrate for P-glycoprotein (P-gp).
            Ritonavir is an inhibitor of CYP3A4 and P-glycoprotein (P-gp). It is metabolized by CYP3A and it is a substrate for P-glycoprotein (P-gp).
TARGET      HCV NS3/4A protease [KO:K22273 K22274]
            HCV NS5A [KO:K22275]
            HCV NS5B [KO:K22472]
            RNA-directed DNA polymerase
  PATHWAY   ko03230(K22273+K22274+K22275+K22472)  Viral genome structure
            ko03240(K22273+K22274+K22275+K22472)  Viral replication
            ko05160(K22273+K22274+K22275+K22472)  Hepatitis C
METABOLISM  Enzyme: CYP3A [HSA:1576 1577 1551], CYP2C8 [HSA:1558]
            Transporter: SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234], ABCB1 [HSA:5243], ABCG2 [HSA:9429]
INTERACTION CYP inhibition: CYP3A4 [HSA:1576]
            Transporter inhibition: SLCO1B1 [HSA:10599], SLCO1B3 [HSA:28234], ABCG2 [HSA:9429]
            Enzyme inhibition: UGT1A1 [HSA:54658]
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AP Antivirals for treatment of HCV infections
                 J05AP52 Dasabuvir, ombitasvir, paritaprevir and ritonavir
                  D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
            USP drug classification [BR:br08302]
             Antivirals
              Anti-hepatitis C (HCV) Agents
               Dasabuvir/ Ombitasvir/ Paritaprevir/ Ritonavir
                D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
            Drug groups [BR:br08330]
             Antiviral
              DG03198  Anti-HCV agent
               D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
             Metabolizing enzyme substrate
              DG02918  CYP2C8 substrate
               D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
              DG01633  CYP3A/CYP3A4 substrate
               D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
             Metabolizing enzyme inhibitor
              DG02852  CYP3A/CYP3A4 inhibitor
               DG01522  CYP3A4 inhibitor
                D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
              DG02887  UGT1A1 inhibitor
               D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
             Transporter substrate
              DG01665  ABCB1 substrate
               D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
              DG01913  ABCG2 substrate
               D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
              DG02856  SLCO1B1 substrate
               D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
              DG02932  SLCO1B3 substrate
               D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
             Transporter inhibitor
              DG02862  ABCG2 inhibitor
               D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
              DG02865  SLCO1B1 inhibitor
               D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
              DG02907  SLCO1B3 inhibitor
               D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
            Antimicrobials [BR:br08307]
             Antivirals
              Polyprotein cleavage inhibitor
               HCV NS3/4A inhibitor
                D10582  Dasabuvir, ombitasvir, paritaprevir and ritonavir
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10582
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10582
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D10582
             Drug transporters
              D10582
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D10582
DBLINKS     PubChem: 254741544
            ChEBI: 85177
///
